<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540825</url>
  </required_header>
  <id_info>
    <org_study_id>1314.1</org_study_id>
    <secondary_id>2011-005034-19</secondary_id>
    <nct_id>NCT01540825</nct_id>
  </id_info>
  <brief_title>First in Man Trial of BI 113608</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113608 in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the safety and tolerability of
      BI 113608 in healthy male volunteers following oral administration of single rising doses.

      A secondary objective is the exploration of the pharmacokinetics of BI 113608 after single
      dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Relevant Abnormalities for Clinical Laboratory Evaluation, Vital Signs, Lung Function, Carbon Monoxide Diffusing Capacity of the Lung, ECG, Physical Examination, Orthostasis Test, Oxygen Saturation or Haemoccult Test</measure>
    <time_frame>From administration of study drug until end-of-study visit, up to 10 days</time_frame>
    <description>Clinically relevant abnormalities for clinical laboratory evaluation, vital signs, lung function, carbon monoxide Diffusing Capacity Of the Lung (DLCO), Electrocardiogram (ECG), physical examination, orthostasis test, oxygen saturation or haemoccult test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Drug-related Adverse Events</measure>
    <time_frame>From administration of study drug until end-of-study visit, up to 10 days</time_frame>
    <description>Percentage of participants with drug-related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Tolerability by the Investigator</measure>
    <time_frame>End of study visit, up to day 10</time_frame>
    <description>Assessment of tolerability by the investigator assessed according to the categories good, satisfactory, not satisfactory, bad and not assessable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
    <description>Maximum measured concentration of the analyte in plasma (Cmax).
The analysis population was the pharmacokinetic (PK) set which included all subjects randomised and treated with study medication who provided at least 1 evaluable observation for a PK endpoint of Area Under the Concentration-time Curve from 0 to infinity (AUC0-inf), Area Under the Concentration-time Curve from 0 to the last quantifiable data point (AUC0-tz) and Cmax and who had no important protocol violations relevant to the evaluation of PK.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
    <description>Time from dosing to maximum measured concentration of the analyte in plasma (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity</measure>
    <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
    <description>Terminal half-life of the analyte in plasma (t1/2)</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 113608 high dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 low dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 low dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 low dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 low dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 medium dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 medium dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 medium dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 high dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 113608 high dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Low dose powder for oral solution</description>
    <arm_group_label>BI 113608 low dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>High dose powder for oral solution</description>
    <arm_group_label>BI 113608 high dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Medium dose powder for oral solution</description>
    <arm_group_label>BI 113608 medium dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Low dose powder for oral solution</description>
    <arm_group_label>BI 113608 low dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powder for oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Low dose powder for oral solution</description>
    <arm_group_label>BI 113608 low dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>High dose powder for oral solution</description>
    <arm_group_label>BI 113608 high dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>High dose powder for oral solution</description>
    <arm_group_label>BI 113608 high dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Medium dose powder for oral solution</description>
    <arm_group_label>BI 113608 medium dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Medium dose powder for oral solution</description>
    <arm_group_label>BI 113608 medium dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Low dose powder for oral solution</description>
    <arm_group_label>BI 113608 low dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <results_first_submitted>November 23, 2016</results_first_submitted>
  <results_first_submitted_qc>November 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2017</results_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received a single dose of a placebo oral solution of volume matching the respective dose group</description>
        </group>
        <group group_id="P2">
          <title>BI 113608 0.5mg</title>
          <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
        </group>
        <group group_id="P3">
          <title>BI 113608 1mg</title>
          <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
        </group>
        <group group_id="P4">
          <title>BI 113608 2mg</title>
          <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
        </group>
        <group group_id="P5">
          <title>BI 113608 5mg</title>
          <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
        </group>
        <group group_id="P6">
          <title>BI 113608 10mg</title>
          <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
        </group>
        <group group_id="P7">
          <title>BI 113608 20mg</title>
          <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
        </group>
        <group group_id="P8">
          <title>BI 113608 50mg</title>
          <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
        </group>
        <group group_id="P9">
          <title>BI 113608 100mg</title>
          <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
        </group>
        <group group_id="P10">
          <title>BI 113608 150mg</title>
          <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
        </group>
        <group group_id="P11">
          <title>BI 113608 200mg</title>
          <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set which included all randomised subjects who received 1 dose of the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received a single dose of a placebo oral solution of volume matching the respective dose group</description>
        </group>
        <group group_id="B2">
          <title>BI 113608 0.5mg</title>
          <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
        </group>
        <group group_id="B3">
          <title>BI 113608 1mg</title>
          <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
        </group>
        <group group_id="B4">
          <title>BI 113608 2mg</title>
          <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
        </group>
        <group group_id="B5">
          <title>BI 113608 5mg</title>
          <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
        </group>
        <group group_id="B6">
          <title>BI 113608 10mg</title>
          <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
        </group>
        <group group_id="B7">
          <title>BI 113608 20mg</title>
          <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
        </group>
        <group group_id="B8">
          <title>BI 113608 50mg</title>
          <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
        </group>
        <group group_id="B9">
          <title>BI 113608 100mg</title>
          <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
        </group>
        <group group_id="B10">
          <title>BI 113608 150mg</title>
          <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
        </group>
        <group group_id="B11">
          <title>BI 113608 200mg</title>
          <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="10.0"/>
                    <measurement group_id="B2" value="29.2" spread="8.1"/>
                    <measurement group_id="B3" value="34.8" spread="6.4"/>
                    <measurement group_id="B4" value="36.8" spread="12.8"/>
                    <measurement group_id="B5" value="28.5" spread="9.5"/>
                    <measurement group_id="B6" value="41.2" spread="4.6"/>
                    <measurement group_id="B7" value="30.5" spread="9.6"/>
                    <measurement group_id="B8" value="37.2" spread="11.8"/>
                    <measurement group_id="B9" value="39.7" spread="11.7"/>
                    <measurement group_id="B10" value="35.3" spread="11.3"/>
                    <measurement group_id="B11" value="38.8" spread="9.2"/>
                    <measurement group_id="B12" value="35.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinically Relevant Abnormalities for Clinical Laboratory Evaluation, Vital Signs, Lung Function, Carbon Monoxide Diffusing Capacity of the Lung, ECG, Physical Examination, Orthostasis Test, Oxygen Saturation or Haemoccult Test</title>
        <description>Clinically relevant abnormalities for clinical laboratory evaluation, vital signs, lung function, carbon monoxide Diffusing Capacity Of the Lung (DLCO), Electrocardiogram (ECG), physical examination, orthostasis test, oxygen saturation or haemoccult test</description>
        <time_frame>From administration of study drug until end-of-study visit, up to 10 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of a placebo oral solution of volume matching the respective dose group</description>
          </group>
          <group group_id="O2">
            <title>BI 113608 0.5mg</title>
            <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
          </group>
          <group group_id="O3">
            <title>BI 113608 1mg</title>
            <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
          </group>
          <group group_id="O4">
            <title>BI 113608 2mg</title>
            <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
          </group>
          <group group_id="O5">
            <title>BI 113608 5mg</title>
            <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
          </group>
          <group group_id="O6">
            <title>BI 113608 10mg</title>
            <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
          </group>
          <group group_id="O7">
            <title>BI 113608 20mg</title>
            <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
          </group>
          <group group_id="O8">
            <title>BI 113608 50mg</title>
            <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
          </group>
          <group group_id="O9">
            <title>BI 113608 100mg</title>
            <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
          </group>
          <group group_id="O10">
            <title>BI 113608 150mg</title>
            <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
          </group>
          <group group_id="O11">
            <title>BI 113608 200mg</title>
            <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Clinical Laboratory Evaluation, Vital Signs, Lung Function, Carbon Monoxide Diffusing Capacity of the Lung, ECG, Physical Examination, Orthostasis Test, Oxygen Saturation or Haemoccult Test</title>
          <description>Clinically relevant abnormalities for clinical laboratory evaluation, vital signs, lung function, carbon monoxide Diffusing Capacity Of the Lung (DLCO), Electrocardiogram (ECG), physical examination, orthostasis test, oxygen saturation or haemoccult test</description>
          <population>Treated set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum measured concentration of the analyte in plasma (Cmax).
The analysis population was the pharmacokinetic (PK) set which included all subjects randomised and treated with study medication who provided at least 1 evaluable observation for a PK endpoint of Area Under the Concentration-time Curve from 0 to infinity (AUC0-inf), Area Under the Concentration-time Curve from 0 to the last quantifiable data point (AUC0-tz) and Cmax and who had no important protocol violations relevant to the evaluation of PK.</description>
        <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>BI 113608 0.5mg</title>
            <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
          </group>
          <group group_id="O2">
            <title>BI 113608 1mg</title>
            <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
          </group>
          <group group_id="O3">
            <title>BI 113608 2mg</title>
            <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
          </group>
          <group group_id="O4">
            <title>BI 113608 5mg</title>
            <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
          </group>
          <group group_id="O5">
            <title>BI 113608 10mg</title>
            <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
          </group>
          <group group_id="O6">
            <title>BI 113608 20mg</title>
            <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
          </group>
          <group group_id="O7">
            <title>BI 113608 50mg</title>
            <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
          </group>
          <group group_id="O8">
            <title>BI 113608 100mg</title>
            <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
          </group>
          <group group_id="O9">
            <title>BI 113608 150mg</title>
            <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
          </group>
          <group group_id="O10">
            <title>BI 113608 200mg</title>
            <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum measured concentration of the analyte in plasma (Cmax).
The analysis population was the pharmacokinetic (PK) set which included all subjects randomised and treated with study medication who provided at least 1 evaluable observation for a PK endpoint of Area Under the Concentration-time Curve from 0 to infinity (AUC0-inf), Area Under the Concentration-time Curve from 0 to the last quantifiable data point (AUC0-tz) and Cmax and who had no important protocol violations relevant to the evaluation of PK.</description>
          <population>PK set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="23.3" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.66" spread="33.2" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="2.83" spread="33.5" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O4" value="7.33" spread="19.4" lower_limit="0.75" upper_limit="4.00"/>
                    <measurement group_id="O5" value="23.5" spread="60.0" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O6" value="52.6" spread="32.9" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O7" value="202" spread="68.5" lower_limit="0.25" upper_limit="6.00"/>
                    <measurement group_id="O8" value="459" spread="69.0" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O9" value="984" spread="24.1" lower_limit="0.75" upper_limit="1.52"/>
                    <measurement group_id="O10" value="1850" spread="16.4" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose). Dose proportionality of BI 113608 (powder in bottle (PIB)) for Cmax was analysed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.2472</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0320</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1831</ci_lower_limit>
            <ci_upper_limit>1.3112</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale. Standard Error of the mean is actually the Standard Error of the slope</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time from dosing to maximum measured concentration of the analyte in plasma (Tmax)</description>
        <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>BI 113608 0.5mg</title>
            <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
          </group>
          <group group_id="O2">
            <title>BI 113608 1mg</title>
            <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
          </group>
          <group group_id="O3">
            <title>BI 113608 2mg</title>
            <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
          </group>
          <group group_id="O4">
            <title>BI 113608 5mg</title>
            <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
          </group>
          <group group_id="O5">
            <title>BI 113608 10mg</title>
            <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
          </group>
          <group group_id="O6">
            <title>BI 113608 20mg</title>
            <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
          </group>
          <group group_id="O7">
            <title>BI 113608 50mg</title>
            <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
          </group>
          <group group_id="O8">
            <title>BI 113608 100mg</title>
            <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
          </group>
          <group group_id="O9">
            <title>BI 113608 150mg</title>
            <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
          </group>
          <group group_id="O10">
            <title>BI 113608 200mg</title>
            <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time from dosing to maximum measured concentration of the analyte in plasma (Tmax)</description>
          <population>PK set</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="2.25" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O4" value="1.75" lower_limit="0.75" upper_limit="4.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O6" value="1.10" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O7" value="0.76" lower_limit="0.25" upper_limit="6.00"/>
                    <measurement group_id="O8" value="0.63" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O9" value="0.75" lower_limit="0.75" upper_limit="1.52"/>
                    <measurement group_id="O10" value="0.63" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)</description>
        <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>BI 113608 0.5mg</title>
            <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
          </group>
          <group group_id="O2">
            <title>BI 113608 1mg</title>
            <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
          </group>
          <group group_id="O3">
            <title>BI 113608 2mg</title>
            <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
          </group>
          <group group_id="O4">
            <title>BI 113608 5mg</title>
            <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
          </group>
          <group group_id="O5">
            <title>BI 113608 10mg</title>
            <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
          </group>
          <group group_id="O6">
            <title>BI 113608 20mg</title>
            <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
          </group>
          <group group_id="O7">
            <title>BI 113608 50mg</title>
            <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
          </group>
          <group group_id="O8">
            <title>BI 113608 100mg</title>
            <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
          </group>
          <group group_id="O9">
            <title>BI 113608 150mg</title>
            <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
          </group>
          <group group_id="O10">
            <title>BI 113608 200mg</title>
            <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)</description>
          <population>PK set</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="23.7" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="11.4" spread="62.3" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="19.1" spread="30.7" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O4" value="53.9" spread="18.3" lower_limit="0.75" upper_limit="4.00"/>
                    <measurement group_id="O5" value="142" spread="24.2" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O6" value="304" spread="24.7" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O7" value="861" spread="34.8" lower_limit="0.25" upper_limit="6.00"/>
                    <measurement group_id="O8" value="1990" spread="40.6" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O9" value="4240" spread="18.2" lower_limit="0.75" upper_limit="1.52"/>
                    <measurement group_id="O10" value="5950" spread="25.9" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose). Dose proportionality of BI 113608 (PIB) for AUC 0− tz was analysed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.1626</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0215</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1195</ci_lower_limit>
            <ci_upper_limit>1.2057</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale. Standard Error of the mean is actually Standard Error of the slope</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-infinity</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)</description>
        <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>BI 113608 0.5mg</title>
            <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
          </group>
          <group group_id="O2">
            <title>BI 113608 1mg</title>
            <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
          </group>
          <group group_id="O3">
            <title>BI 113608 2mg</title>
            <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
          </group>
          <group group_id="O4">
            <title>BI 113608 5mg</title>
            <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
          </group>
          <group group_id="O5">
            <title>BI 113608 10mg</title>
            <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
          </group>
          <group group_id="O6">
            <title>BI 113608 20mg</title>
            <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
          </group>
          <group group_id="O7">
            <title>BI 113608 50mg</title>
            <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
          </group>
          <group group_id="O8">
            <title>BI 113608 100mg</title>
            <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
          </group>
          <group group_id="O9">
            <title>BI 113608 150mg</title>
            <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
          </group>
          <group group_id="O10">
            <title>BI 113608 200mg</title>
            <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)</description>
          <population>PK set</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" spread="23.3" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="12.2" spread="60.3" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="19.9" spread="28.7" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O4" value="55.2" spread="18.8" lower_limit="0.75" upper_limit="4.00"/>
                    <measurement group_id="O5" value="144" spread="23.2" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O6" value="307" spread="25.2" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O7" value="862" spread="34.7" lower_limit="0.25" upper_limit="6.00"/>
                    <measurement group_id="O8" value="1990" spread="40.6" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O9" value="4250" spread="18.2" lower_limit="0.75" upper_limit="1.52"/>
                    <measurement group_id="O10" value="5960" spread="25.9" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose).Dose proportionality of BI 113608 (PIB) for AUC0-inf was analysed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.1510</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0215</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1080</ci_lower_limit>
            <ci_upper_limit>1.1941</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model (ANCOVA). The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale. Standard Error of the mean is actually Standard Error of the slope</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>Terminal half-life of the analyte in plasma (t1/2)</description>
        <time_frame>Before drug administration and 15minutes (min), 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 34h, 48h and 72h (for doses &gt;=50mg only) after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>BI 113608 0.5mg</title>
            <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
          </group>
          <group group_id="O2">
            <title>BI 113608 1mg</title>
            <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
          </group>
          <group group_id="O3">
            <title>BI 113608 2mg</title>
            <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
          </group>
          <group group_id="O4">
            <title>BI 113608 5mg</title>
            <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
          </group>
          <group group_id="O5">
            <title>BI 113608 10mg</title>
            <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
          </group>
          <group group_id="O6">
            <title>BI 113608 20mg</title>
            <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
          </group>
          <group group_id="O7">
            <title>BI 113608 50mg</title>
            <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
          </group>
          <group group_id="O8">
            <title>BI 113608 100mg</title>
            <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
          </group>
          <group group_id="O9">
            <title>BI 113608 150mg</title>
            <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
          </group>
          <group group_id="O10">
            <title>BI 113608 200mg</title>
            <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Terminal half-life of the analyte in plasma (t1/2)</description>
          <population>PK set</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="22.4" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="8.10" spread="38.0" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="8.56" spread="17.5" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O4" value="8.08" spread="39.6" lower_limit="0.75" upper_limit="4.00"/>
                    <measurement group_id="O5" value="10.3" spread="24.2" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O6" value="9.51" spread="26.6" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O7" value="11.2" spread="7.54" lower_limit="0.25" upper_limit="6.00"/>
                    <measurement group_id="O8" value="12.8" spread="11.2" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O9" value="12.5" spread="15.6" lower_limit="0.75" upper_limit="1.52"/>
                    <measurement group_id="O10" value="11.8" spread="12.9" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Drug-related Adverse Events</title>
        <description>Percentage of participants with drug-related adverse events</description>
        <time_frame>From administration of study drug until end-of-study visit, up to 10 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of a placebo oral solution of volume matching the respective dose group</description>
          </group>
          <group group_id="O2">
            <title>BI 113608 0.5mg</title>
            <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
          </group>
          <group group_id="O3">
            <title>BI 113608 1mg</title>
            <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
          </group>
          <group group_id="O4">
            <title>BI 113608 2mg</title>
            <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
          </group>
          <group group_id="O5">
            <title>BI 113608 5mg</title>
            <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
          </group>
          <group group_id="O6">
            <title>BI 113608 10mg</title>
            <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
          </group>
          <group group_id="O7">
            <title>BI 113608 20mg</title>
            <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
          </group>
          <group group_id="O8">
            <title>BI 113608 50mg</title>
            <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
          </group>
          <group group_id="O9">
            <title>BI 113608 100mg</title>
            <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
          </group>
          <group group_id="O10">
            <title>BI 113608 150mg</title>
            <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
          </group>
          <group group_id="O11">
            <title>BI 113608 200mg</title>
            <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Drug-related Adverse Events</title>
          <description>Percentage of participants with drug-related adverse events</description>
          <population>Treated set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="50.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Tolerability by the Investigator</title>
        <description>Assessment of tolerability by the investigator assessed according to the categories good, satisfactory, not satisfactory, bad and not assessable.</description>
        <time_frame>End of study visit, up to day 10</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of a placebo oral solution of volume matching the respective dose group</description>
          </group>
          <group group_id="O2">
            <title>BI 113608 0.5mg</title>
            <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
          </group>
          <group group_id="O3">
            <title>BI 113608 1mg</title>
            <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
          </group>
          <group group_id="O4">
            <title>BI 113608 2mg</title>
            <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
          </group>
          <group group_id="O5">
            <title>BI 113608 5mg</title>
            <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
          </group>
          <group group_id="O6">
            <title>BI 113608 10mg</title>
            <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
          </group>
          <group group_id="O7">
            <title>BI 113608 20mg</title>
            <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
          </group>
          <group group_id="O8">
            <title>BI 113608 50mg</title>
            <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
          </group>
          <group group_id="O9">
            <title>BI 113608 100mg</title>
            <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
          </group>
          <group group_id="O10">
            <title>BI 113608 150mg</title>
            <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
          </group>
          <group group_id="O11">
            <title>BI 113608 200mg</title>
            <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Tolerability by the Investigator</title>
          <description>Assessment of tolerability by the investigator assessed according to the categories good, satisfactory, not satisfactory, bad and not assessable.</description>
          <population>Treated set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="100"/>
                    <measurement group_id="O9" value="100"/>
                    <measurement group_id="O10" value="100"/>
                    <measurement group_id="O11" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From administration of study drug until end-of-study visit, up to 10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received a single dose of a placebo oral solution of volume matching the respective dose group</description>
        </group>
        <group group_id="E2">
          <title>BI 113608 0.5mg</title>
          <description>Participants received a single dose of BI 113608 0.5mg powder for oral solution</description>
        </group>
        <group group_id="E3">
          <title>BI 113608 1mg</title>
          <description>Participants received a single dose of BI 113608 1mg powder for oral solution</description>
        </group>
        <group group_id="E4">
          <title>BI 113608 2mg</title>
          <description>Participants received a single dose of BI 113608 2mg powder for oral solution</description>
        </group>
        <group group_id="E5">
          <title>BI 113608 5mg</title>
          <description>Participants received a single dose of BI 113608 5mg powder for oral solution</description>
        </group>
        <group group_id="E6">
          <title>BI 113608 10mg</title>
          <description>Participants received a single dose of BI 113608 10mg powder for oral solution</description>
        </group>
        <group group_id="E7">
          <title>BI 113608 20mg</title>
          <description>Participants received a single dose of BI 113608 20mg powder for oral solution</description>
        </group>
        <group group_id="E8">
          <title>BI 113608 50mg</title>
          <description>Participants received a single dose of BI 113608 50mg powder for oral solution</description>
        </group>
        <group group_id="E9">
          <title>BI 113608 100mg</title>
          <description>Participants received a single dose of BI 113608 100mg powder for oral solution</description>
        </group>
        <group group_id="E10">
          <title>BI 113608 150mg</title>
          <description>Participants received a single dose of BI 113608 150mg powder for oral solution</description>
        </group>
        <group group_id="E11">
          <title>BI 113608 200mg</title>
          <description>Participants received a single dose of BI 113608 200mg powder for oral solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Retrograde amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

